Indeed, the early onset of treatment with zinc chelating agents is expected to protect from the deleterious systemic ACE2 upregulation, which is early induced by SARS-CoV-2; this inhibitory activity will possibly reduce both the period of infection and the potential adverse effects of long-term treatments, hopefully rendering COVID-19 like a simple coronavirus cold, an immune eradicable disease. This evidence concerns the gene ACE2 and COVID-19.